Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial.

ABSTRACT:

Introduction

The Oncotype Dx Genomic Prostate Score (GPS) is a 17-gene relative expression assay that predicts adverse pathology at prostatectomy. We conducted a novel randomized controlled trial to assess the impact of GPS on urologist's treatment preference for favorable risk prostate cancer (PCa): active surveillance versus active treatment (i.e., prostatectomy/radiation). This is a secondary endpoint from the ENACT trial which recruited from three Chicago hospitals from 2016 to 2019.

Methods

Ten urologists along with men with very low to favorable-intermediate risk PCa were included in the study. Participants were randomly assigned to standardized counseling with or without GPS assay. The main outcome was urologists' preference for active treatment at Visit 2 by study ar

SUBMITTER: Carbunaru S 

PROVIDER: S-EPMC10587942 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature